JCO Precision Oncology

Journal

Overview
Identity

Publication Venue For

Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.. 7:e2200505. 2023

Germline Genetic and Treatment-Related Risk Factors for Diabetes Mellitus in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study and St Jude Lifetime Cohorts.. 6:e2200239. 2022

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.. 6:e2200165. 2022

Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.. 5. 2021

GPS Assay association with long-term cancer outcomes: Twenty-year risk of distant metastasis and prostate cancer-specific mortality. 5:442-449. 2021

Subsequent neoplasm risk associated with rare variants in DNA damage response and clinical radiation sensitivity syndrome genes in the childhood cancer survivor study. 4:926-936. 2020

Activity of brigatinib in crizotinib and ceritinib-resistant ROS1- rearranged non-small-cell lung cancer. 3:1-6. 2019

Individualized screening trial of innovative glioblastoma therapy (INSIGhT): A Bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma. 3:1-13. 2019

Electronic International Standard Serial Number (eissn)

2473-4284